Recent partnership announcements in the pharma industry reflects the community’s commitment to collaborative innovation, ...

In today’s Pharmaceutical Executive Daily, we cover Kimberly-Clark’s $48.7 billion acquisition of Kenvue, Cencora’s $1 ...

Novo Nordisk’s amended proposal values Metsera at $86.20-per-share, for a total value upwards of $10 billion, representing an ...

In the third entry of Pharmacuetical Executive’s premium webinar series examining the impact of President Trump’s MFN ...

Raj Indupuri, CEO, eClinical Solutions,emphasized that robust data strategy and infrastructure are essential for realizing AI ...

UCB has announced FDA’s approval of Kygevvi (doxecitine and doxribtimine) for the treatment of adults and pediatric patients ...

In today’s Pharmaceutical Executive Daily, we cover Pfizer’s lawsuits against Metsera and Novo Nordisk over alleged ...

Manifold Bio announced a strategic research collaboration and license agreement with Roche, aiming to apply Manifold's tissue ...

PE: How long will it take for the market to be impacted by FDA's ANDA Prioritization Pilot? Botha: It’s a relative window. It ...

The final session of Pharmaceutical Executive’s and MJH Life Sciences’ three-part webinar series on President Trump’s “Most ...

Raj Indupuri, CEO, eClinical Solutions,pharma’s biggest AI adoption hurdles lie in scaling beyond pilots, ensuring data ...

Pfizer's lawsuits target Metsera, its directors, and Novo Nordisk for breach of contract and antitrust violations, focusing ...